Page 164 - Mployee Wellness Programs News Today

With more people now covered by the ACA than ever, health plans have an unprecedented opportunity to make a lasting impact on public health by encouraging members to take advantage of a

In the EU, there is a widespread distrust of American tech companies, according to a recent conference presentation by an international healthcare lawyer. Because of this, the EU has established a number of new laws protecting its citizens' data privacy and creating frameworks for the secure exchange of information — laws that American health tech companies will have to comply with if they do business in the EU.

By evaluating the potential of healthcare operations software investments to affect each of these three key outcomes areas — patient outcomes, workforce outcomes, and risk and compliance outcomes — CIOs can make informed decisions that drive value and improve outcomes for patients, providers, and the entire organization. 

Ultimately, the question is whether technology can provide a positive path forward. The answer will not rest in the capabilities of the modern EHR.

SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.

Vertex Pharmaceuticals aims to CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete with a Sana Biotechnology program expected to reach its first test in humans this year.

During a panel at the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum, three executives were asked what gives them comfort about the return to Medicaid redeterminations, as well as what worries them. One CMS official said she's pleased that states are ramping up communication efforts for Medicaid enrollees, but is concerned about the "insurmountable task" ahead.

In recent years, manufacturers have restricted access to 340B pricing for drugs dispensed through contract pharmacies. The federal government has advised manufacturers that such restrictions are unlawful, and manufactures have challenged government enforcement actions in federal court.

Pharming Group drug Joenja was awarded FDA approval for treating a primary immunodeficiency called activated phosphoinositide 3-kinase delta syndrome, or APDS. It’s the first treatment for the rare disorder.

To build remote patient monitoring technology for ready adoption, repetitive data streams must be avoided. To be successful in clinical adoption, we offer technology companies the following three recommendations.